10x Genomics, Inc. reaffirmed revenue guidance for the year 2024. The company maintaining its previously announced full year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.78 USD | -0.72% | -8.60% | -59.15% |
May. 15 | Transcript : 10x Genomics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM | |
May. 07 | Bruker's NanoString Secures Patent Case Win in Germany | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.15% | 2.75B | |
-4.92% | 12.11B | |
-5.82% | 8.07B | |
+5.43% | 5.67B | |
+27.77% | 5.48B | |
-9.58% | 4.12B | |
+8.44% | 2.62B | |
-3.70% | 2.33B | |
+21.06% | 2.11B | |
-7.49% | 1.83B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024